Cambridge Healthtech Institute’s 3rd Annual

Emerging Indications for Therapeutic Antibodies

R&D Advances in Non-Cancer Indications for Antibodies and Other Biotherapeutics

May 4-5, 2020

Significant scientific advances in the fields of immunology and protein science are driving the development of biotherapeutic drugs in a growing range of therapeutic areas beyond oncology. These advances support the identification of new and unique targets, new approaches to developing biotherapeutics for unserved medical needs, methods of binding to illusive targets and translational science for patient stratification and drug development for niche indications. The PEGS Emerging Indications for Therapeutic Antibodies conference provides a forum for research organizations with diverse portfolios to explore new science and technology in the development of a next generation of safe and effective therapeutics in an important set of emerging indications.

Preliminary Agenda


Development of a Novel Therapeutic Antibody-Drug Conjugate for the Treatment of Autoimmune Disease

Michael J. McPherson, PhD, Senior Principal Research Scientist, In Vitro Technologies and iADCs, AbbVie

Engineered Antibody Platforms for Receptor Agonism

Greg Lazar, PhD, Director and Senior Scientist, Antibody Engineering, Genentech

Complement Mediation as a Therapeutic Strategy in Autoimmune and Inflammatory Diseases

Claire Harris, PhD, Professor, Molecular Immunology, Newcastle University, United Kingdom


Dissecting the Beta-Amyloid Outcomes: What Was Responsible?

Charles Glabe, PhD, Professor, Molecular Biology and Biochemistry, University of California, Irvine

Preclinical Characterization of a Brain Shuttle Anti-Amyloid Antibody

Jens Niewoehner, PhD, Senior Principal Scientist, Pharmaceutical Research and Early Development, Roche, Germany


KEYNOTE PRESENTATION: Opportunities and Challenges in Biotherapeutic Discovery and Development for Rare Diseases

Madhu Natarajan, PhD, Head, Rare Diseases DDU, Takeda


New Biotherapeutic Approaches for Targeting PCSK9

Robert Giugliano, MD, MSc, Associate Professor, Medicine, Harvard Medical School

Structure-Guided Discovery of a Single Domain Antibody Agonist against Human Apelin Receptor for Chronic Heart Failure

Mei-Yun Zhang, PhD, Principal Scientist, Antibody Discovery, Amgen, China

The Adipocyte as a Source for Novel Targets for Therapeutic Antibodies for Metabolism, Fibrosis and Cancer

Philipp Scherer, PhD, Professor, Internal Medicine, UT Southwestern


Microfluidic Technologies to Capture and Screen B Cell Repertoires for Flu Indications

Sarav Rajan, PhD, Senior Scientist, AstraZeneca

Antibody-Based Scaffolds to Activate T Cells Targeting CMV and EBV

Elissa Leonard, PhD, Postdoctoral Fellow, Biomedical Engineering, Johns Hopkins University

Engineering Antimicrobial Proteins: Co-Evolutionary Models Aid Molecular Discovery

Benjamin Hackel, Associate Professor, Chemical Engineering and Materials Science, University of Minnesota


Antibody Pliers: A Novel Antibody MOA for Asthma

JT Koerber, PhD, Senior Scientist, Antibody Engineering, Genentech

Protein Crystallization Promotes Type 2 Immunity and Is Reversible by Antibody Treatment

Bas van der Woning, PhD, Research Fellow, arGEN-X, Belgium


Engineering a Novel Platform for Tissue-Specificity in Regenerative Medicine

Zhengjian Zhang, PhD, Senior Scientist, Surrozen, Inc.

Progress in Crossing the Blood-Brain Barrier

Eric Shusta, PhD, Professor, Chemical and Biological Engineering, University of Wisconsin-Madison

* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Traditional Chinese
Simplified Chinese

Update History
Sponsor updated

View By: